Welcome to our dedicated page for Bruker SEC filings (Ticker: BRKRP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Bruker Corporation 6.375% Mandatory Convertible Preferred Stock (BRKRP) filings page on Stock Titan is designed to organize and interpret regulatory information related to this preferred equity and its issuer, Bruker Corporation. While no specific SEC filings are listed here in the available data, Bruker’s public communications provide important context for understanding BRKRP as a mandatory convertible preferred security with a stated dividend rate of 6.375%.
In its announcements, Bruker has disclosed a quarterly cash dividend of $3.6745 per share on its 6.375% Mandatory Convertible Preferred Stock, Series A. Regulatory filings associated with such securities typically include the original registration statements and prospectus describing the preferred stock terms, including dividend provisions, conversion mechanics, and rights relative to common stock. Periodic reports often discuss capital structure, preferred stock dividends, and any changes affecting holders of BRKRP.
For a company like Bruker, which emphasizes high-performance scientific instruments and analytical and diagnostic solutions, core SEC filings such as annual reports on Form 10-K and quarterly reports on Form 10-Q can also provide narrative and quantitative detail on its operations in post-genomic life science research, applied and biopharma applications, microscopy and nanoanalysis, industrial and cleantech research, semiconductor metrology, and clinical and molecular diagnostics. These documents help place the BRKRP preferred stock within the broader financial and operational picture of the issuer.
On Stock Titan, AI-powered tools can assist in summarizing lengthy filings, highlighting sections that relate to preferred stock terms, dividend policies, and capital structure, as well as identifying disclosures relevant to Bruker’s scientific and diagnostic activities. This can help readers more quickly locate information that matters for evaluating BRKRP and understanding how regulatory disclosures reflect Bruker’s business and financing choices.
BRUKER CORP director William A. Linton received an equity award of 4,520 restricted stock units (RSUs). The RSUs were granted at no cash cost and relate to the company’s common stock. After this grant, he directly holds 63,243 shares of common stock.
The footnote explains that these RSUs will vest in a single installment on February 15, 2027, and each RSU will automatically convert into one share of Bruker common stock at that time, aligning the director’s compensation more closely with future shareholder value.
Bruker Corp director Adelene Q. Perkins received an equity award of 4,520 restricted stock units (RSUs) of Common Stock on February 15, 2026. The RSUs will vest in a single installment on February 15, 2027, and each unit will convert into one share of Common Stock at vesting. After this grant, Perkins beneficially owns 29,144 shares of Common Stock directly.
BRUKER CORP director Richard A. Packer received an equity award covering 4,520 shares of common stock as a grant of Restricted Stock Units. The RSUs will vest in a single installment on February 15, 2027, at which time each unit will convert into one share of common stock. After this award, Packer’s directly held common stock, including this grant, is reported at 93,694 shares. The grant was recorded at a price of $0.00 per share, consistent with a stock-based compensation award rather than an open-market purchase.
BRUKER CORP director Cynthia M. Friend reported an equity award of 4,520 units tied to Common Stock. The award is structured as Restricted Stock Units (RSUs) that were granted at no cash cost on the transaction date. All 4,520 RSUs will vest in a single installment on February 15, 2027, and each RSU will automatically convert into one share of Common Stock at that time. Following this grant, she now directly holds 22,536 shares of Common Stock, reflecting her updated ownership position.
BRUKER CORP director Bob Rosenthal reported an equity award. He acquired 4,520 shares of Common Stock through a grant classified as a grant, award, or other acquisition at a stated price of $0.00 per share.
According to the footnote, this grant is in the form of Restricted Stock Units that will vest in one installment on February 15, 2027. On the vesting date, each RSU will automatically convert into one share of Common Stock. After this award, Rosenthal directly holds 38,781 shares of Common Stock.
Bruker Corp director Hermann Fritz Requardt received an equity grant of 4,520 shares of Common Stock in the form of restricted stock units. The award was granted at a price of $0.00 per share on February 15, 2026 as compensation rather than an open-market purchase.
The RSUs will vest in one installment on February 15, 2027, at which time each unit will automatically convert into one share of Bruker Common Stock. Following this grant, Requardt holds 30,965 shares of Common Stock in direct ownership, aligning his interests more closely with shareholders.
BRUKER CORP Chief Accounting Officer Thomas Bures reported a tax-related share disposition. On the reported date, 274 shares of common stock were withheld at a price of $36.51 per share to satisfy tax withholding obligations tied to previously granted restricted stock units that vested. After this withholding transaction, Bures directly owned 3,198 shares of Bruker common stock, reflecting a routine, non-open-market adjustment for taxes rather than an elective share sale.
Bruker Corp executive Mark Munch reported option exercises and a share sale. On February 13, he exercised stock options for 2,000 shares, converting derivative securities into common stock at a price of $22.19 per share. He then sold 2,000 common shares at $36.94 per share in an open-market transaction pursuant to a Rule 10b5-1 trading plan.
Following these transactions, he directly owned 128,443 shares of Bruker common stock and held 14,000 stock options.
BRUKER CORP director Bonnie H. Anderson reported an equity award of 4,520 shares of Common Stock. The award was made at a price of $0.00 per share as a grant or other acquisition. Following this award, she reports beneficial ownership of 17,847 Common Stock shares.
According to the filing, the grant is in the form of Restricted Stock Units that will vest in a single installment on February 15, 2027. On that vesting date, each RSU will automatically convert into an equal number of shares of Bruker common stock.
Bruker Corp received an updated ownership report showing that Orbis Investment Management Ltd, Allan Gray Australia Pty Ltd, and Orbis Investment Management (U.S.) L.P. together beneficially own 14,906,730 shares of Bruker common stock, representing 9.8% of the outstanding class.
Orbis Investment Management Ltd reports sole voting and dispositive power over 14,077,895 shares, Allan Gray Australia over 22,092 shares, and Orbis Investment Management (U.S.) L.P. over 806,743 shares. The firms certify the holdings are in the ordinary course of business and not for the purpose of changing or influencing control of Bruker.